FDA sends 30 telehealth companies warning letters over compounded GLP‑1 claims

What happened

FDA announced on March 3, 2026 that it had issued warning letters to 30 telehealth companies concerning claims on their websites about compounded GLP-1 products. The agency described the promotion it reviewed as false or misleading under federal law.

FDA highlighted two recurring problems. Some websites described a compounded medicine as a generic version of an approved drug or otherwise suggested the products were the same. Other sites used company branding in a way that could imply the telehealth platform itself compounded the medicine, without clearly identifying the actual compounder.

Those distinctions matter because an approved generic completes FDA review before marketing, while a compounded drug is not FDA-approved. FDA does not verify a compounded product's safety, effectiveness, or quality before it reaches the market. Compounding can still serve a legitimate clinical need in circumstances allowed by federal and state law.

The agency's telehealth promotion page tells companies that prescription-drug claims must be truthful, accurate, and not misleading. It also states that risk information cannot be omitted or minimized when a business promotes a drug. The public warning-letter database provides the individual correspondence and can later reflect closeout or other follow-up activity.

What it means

The action focuses on advertising and disclosure. FDA is telling online health businesses that an unapproved compounded product cannot be marketed as if it has the same regulatory status as an approved brand or approved generic. A platform's role and the identity of the entity making the product also must not be obscured.

For readers, the central takeaway is narrower than a judgment about telehealth as a whole. A polished website, branded treatment name, or comparison with an approved medicine does not itself show that FDA evaluated the offered product.

What it does not mean

In this context, FDA's correspondence records the agency's position and asks the recipient to address cited issues. It is not a criminal conviction, civil judgment, or final finding by a court. A company's response or later correction can change the status of an individual matter.

The batch does not prove that every telehealth service or every compounded prescription violates the law. It also does not change the approval status of FDA-approved Wegovy, Ozempic, Zepbound, or Mounjaro. The count refers to the letters in the agency's March announcement, not every enforcement action before or after that date.